Cohance Lifesciences Limited (BOM:543064)

Market Cap	363.73B
Revenue (ttm)	11.98B
Net Income (ttm)	2.68B
Shares Out	n/a
EPS (ttm)	10.45
PE Ratio	135.78
Forward PE	55.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,966
Average Volume	4,828
Open	981.85
Previous Close	941.25
Day's Range	937.65 - 981.85
52-Week Range	911.00 - 1,359.00
Beta	n/a
RSI	38.42
Earnings Date	Aug 8, 2025

About Cohance Lifesciences

Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research services. It also manufactures finished dosage formulations for pharmaceutical companies; and specialty chemicals, such as electronic chemicals. The company ...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,193
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.